Incyte Corporation

Ken Mukai

Wenqing Yao

Liangxing Wu

Qinda Ye

Jingwei Li

Yingnan Chen

Min Ye

Margaret Favata

Yvonne Lo

Brandon Smith

Xiaozhao Wang

Wenyu Zhu

Neil Lajkiewicz

Peter Niels Carlsen

Haolin Yin

The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Hetero-tricyclic compounds as inhibitors of KRAS

The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), of Formula (I): as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Tricyclic amine compounds as CDK2 inhibitors

The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Growing community of inventors

Wilmington, DE, United States of America

Ken Mukai